G. Michael Felker <br/><br/>
Heart Failure  A Companion to Braunwald's Heart Disease  

 - 3rd, edition 
 - 1600 John F. Kennedy Blvd. Ste 1800 Philadelphia, PA 19103-2899:   Elsevier Health Sciences,   c2016 
 - 757 pages  
<br/><br/> Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald’s Heart Disease helps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients.<br/><br/>    Focuses on a clinical approach to treating heart failure, resulting from a broad variety of cardiovascular problems.<br/><br/>    Covers the most recent guidelines and protocols, including significant new updates to ACC, AHA, and HFSA guidelines.<br/><br/>    Covers key topics such as biomarkers and precision medicine in heart failure and new data on angiotensin receptor neprilysin inhibitors (ARNIs).<br/><br/>    Contains four new chapters: Natriuretic Peptides in Heart Failure; Amyloidosis as a Cause of Heart Failure; HIV and Heart Failure; and Neuromodulation in Heart Failure.<br/><br/>    Covers the pathophysiological basis for the development and progression of heart failure.<br/><br/>    Serves as a definitive resource to prepare for the ABIM’s Heart Failure board exam.<br/>    2016 British Medical Association Award: First Prize, Cardiology (3rd Edition). 
<br/><br/><label>ISBN: </label>978-1-4557-7237-7 
 = Common terms and phrases  activation acute addition alterations angiotensin artery associated blood Ca2+ cardiac Cardiol cardiomyocyte cardiomyopathy cardiovascular cause cell changes Chapter chronic heart failure Circulation clinical Coll Cardiol contractile contribute coronary death decreased diastolic dilated disease dysfunction effects ejection fraction endothelial enzyme et al evidence exercise expression factor failing fibrosis function gene genetic glucose growth heart failure HFpEF HFrEF human hypertension hypertrophy impaired important improved increased induced infarction inhibition involvement kinase lead left ventricular levels matrix mechanisms mediated mice mitochondrial mortality mutations myocardial myocardial infarction myocardium myocyte myosin normal observed occur outcomes oxidative pathways patients peptide Physiol potential present preserved pressure progression protein receptor reduced regulation release remodeling renal reported response risk role severe showed shown signaling skeletal muscle specific stimulation stress studies suggest sympathetic systolic therapy tion tissue transcription treatment trial vascular volume 
<br/><br/><label>Subjects--Personal Names: </label>--   Medical / Cardiology--	Medical  › Cardiology--Heart Failure
<br/><br/><label>LC Class. No.: </label>WG 370] RC681 
<br/><br/><label>Dewey Class. No.: </label>616.1′2